ERBB2 and cancer: According to the biological type of cancer, the patients were categorised into five groups: luminal A (20 women, 33%); luminal B, HER2-positive (6 women, 10%); luminal B, HER2-negative (22 women, 37%); triple-negative breast cancer (TNBC) (7 women, 12%); and non-luminal, HER2-positive (5 women, 8%).